_1137.png?v=1788503569)
Breaking News
The contentious debate around semaglutide in South African healthcare extends beyond its use for obesity and type 2 diabetes, exposing deep-seated issues of access, affordability, regulation, and the pharmaceutical industry's role. At its core, the discussion highlights a significant deficit in public trust in the institutions responsible for health. Read the full article
As it rages, the semaglutide debate exposes public trust deficit in healthcare
The contentious debate around semaglutide in South African healthcare extends beyond its use for obesity and type 2 diabetes, exposing deep-seated issues of access, affordability, regulation, and the pharmaceutical industry's role. At its core, the discussion...
The contentious debate around semaglutide in South African healthcare extends beyond its use for obesity and type 2 diabetes, exposing deep-seated issues of access, affordability, regulation, and the pharmaceutical industry's role. At its core, the discussion highlights a significant deficit in public trust in the institutions responsible for health.
Read the full articleRead the full article at Mail and Guardian
Article details
- Published
- July 23, 2026
- Last updated
- October 16, 2026
- Written by
- Wade Wilson
- Category
- Health and Foods
- Reading time
- 1 min read
- Views
- 1
